Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26

Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26
Can Taste Loss Be Managed? TALISMAN Study Shares New Answers for Talquetamab Patients | EHA 2026
Top Myeloma Updates from EHA 2026: New Therapies,Trials & Emerging Treatments | EHA 2026
TRIlogy-4: Ramantamig’s Triple Target Attack on Myeloma—BCMA, GPRC5D, and CD3 #EHA2026
SUCCESSOR-2 Trial: Mezigdomide Triplet Shows Powerful Results in Relapse/Refractory Multiple Myeloma
How to Protect Your Medical Records and Insurance From Theft: Being Your Own Private Eye
How to Protect Your Medical Records and Insurance From Theft: Being Your Own Private Eye
REST Trial: Can Higher Revlimid Doses Safely Improve Outcomes in Myeloma Patients w/ Kidney Disease
What are Patient Reported Outcomes (PRO) and why are they being incorporated?
Smoldering Multiple Myeloma EHA Highlights: Multiple Options as Treatment | EHA 2026
Relapsed/Refractory Multiple Myeloma Highlights from EHA | EHA 2026